Market Chatter: Eli Lilly CEO Says One-Third of New GLP-1 Pill Patients Starting on Foundayo

01:50 PM EDT, 09/21/2026 (MT Newswires) -- Eli Lilly's (LLY) oral drug Foundayo now makes up one-third of new GLP-1 pill patients, CNBC reported Monday, citing CEO Dave Ricks. Ricks told CNBC the company's share of the oral market is growing week over week, and said Lilly is "confident long term" about its position as it prepares to launch Foundayo in additional international markets, according to the report. Lilly broke ground on a $6.5 billion Houston manufacturing plant expected to be operational by 2030, the report said. Eli Lilly did not immediately respond to a request for comment from MT Newswires. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) Price: 1167.10, Change: +14.17, Percent Change: +1.23